SCHEMBL5959226

SCHEMBL5959226

COC(=O)c1ccc(C(=O)c2cc(C#N)c3ccc4ccccc4n23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.43
▸ PTPN1 P18031 2/20 0.42
▸ CDC25A P30304 2/20 0.42
▸ DUSP3 P51452 2/20 0.42
▸ EGFR P00533 2/20 0.40
▸ SRC P12931 1/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ RAPGEF3 O95398 1/20 0.38
▸ TSHR P16473 1/20 0.37
▸ MAPT P10636 2/20 0.37
▸ FGFR1 P11362 1/20 0.36
▸ GAA P10253 2/20 0.36
▸ PLAU P00749 2/20 0.36
▸ POLB P06746 2/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ HBB P68871 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5312235 0.89 NPC1 (0.42) PTPN1CDC25ADUSP3MAPK1ALDH1A1
SCHEMBL5959209 0.87 MAPK1 (0.44) PTPN1CDC25ADUSP3MAPK1ALDH1A1
SCHEMBL5310989 0.87 PTPN1 (0.44) PTPN1CDC25ADUSP3MAPK1ALDH1A1
SCHEMBL5257352 0.86 PTPN1 (0.40) PTPN1CDC25ADUSP3MAPK1
SCHEMBL5313502 0.85 LMNA (0.41) PTPN1CDC25ADUSP3MAPK1ALDH1A1
SCHEMBL5959251 0.85 FNTA (0.44) PTPN1CDC25ADUSP3MAPK1ALDH1A1
SCHEMBL5959278 0.85 KMT2A (0.46) PTPN1CDC25ADUSP3MAPK1ALDH1A1
SCHEMBL5308585 0.85 MAPK1 (0.39) PTPN1CDC25ADUSP3MAPK1ALDH1A1
SCHEMBL5256707 0.84 ALDH1A1 (0.45) PTPN1CDC25ADUSP3MAPK1ALDH1A1
SCHEMBL5313611 0.83 KMT2A (0.48) PTPN1CDC25ADUSP3ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135480-B2 Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers CYTOVIA, INC. (US) 2006-11-14 — — US disclosed
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2005-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CASP3, CASP7, CASP1 THRB 4548/4885PTPN1 578/4885CDC25A 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback